NASDAQ:SONN Sonnet BioTherapeutics Q3 2024 Earnings Report ProfileEarnings HistoryForecast Sonnet BioTherapeutics EPS ResultsActual EPS-$5.60Consensus EPS -$6.08Beat/MissBeat by +$0.48One Year Ago EPSN/ASonnet BioTherapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASonnet BioTherapeutics Announcement DetailsQuarterQ3 2024Date8/14/2024TimeBefore Market OpensConference Call DateWednesday, August 14, 2024Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Sonnet BioTherapeutics Earnings HeadlinesHyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business CombinationDecember 2, 2025 | globenewswire.comSonnet BioTherapeutics stockholders approve Hyperliquid Strategies combinationDecember 2, 2025 | msn.comElon Musk’s $1 Quadrillion AI IPO$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.And right now, you can claim a stake before the company goes public, starting with just $500.Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today. | Brownstone Research (Ad)Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies IncDecember 2, 2025 | finance.yahoo.comSonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special MeetingNovember 18, 2025 | globenewswire.comSonnet BioTherapeutics Announces Special Meeting for Business Combination VoteOctober 29, 2025 | msn.comSee More Sonnet BioTherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sonnet BioTherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sonnet BioTherapeutics and other key companies, straight to your email. Email Address About Sonnet BioTherapeuticsSonnet BioTherapeutics (NASDAQ:SONN) is a clinical-stage biotechnology company dedicated to developing innovative cytokine-based therapeutics for oncology and autoimmune disorders. The company’s platform centers on engineering human cytokines, notably interleukin-2 and related molecules, fused to carrier proteins such as human serum albumin. This design aims to extend circulating half-life, enhance tumor localization, and minimize systemic toxicity compared with traditional cytokine therapies. Sonnet’s lead pipeline candidates are in early-phase clinical trials for the treatment of solid tumors, where the company seeks to demonstrate improved efficacy and safety. In parallel, Sonnet is advancing preclinical immunocytokine programs targeting specific aspects of the tumor microenvironment to further leverage its fusion protein technology across multiple cancer indications. Headquartered in San Diego, California, Sonnet BioTherapeutics conducts research and development operations in the United States. The management team comprises seasoned industry professionals with expertise in immuno-oncology, biologics development, and clinical strategy, positioning the company to progress its pipeline toward later-stage trials and potential partnerships.View Sonnet BioTherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?Workday Validates AI Flywheel: Stock Price Recovery BeginsOverextended, e.l.f. Beauty Is Primed to Rebound in Back HalfDeere Beats Q2 Estimates, But Ag Weakness Weighs on OutlookNVIDIA Price Pullback? Don’t Count on It, Business Is AcceleratingMeta Platforms 10% Layoff Raises a Bigger Question About AI SpendingBiogen Stock Slides After Trial Miss, But Analysts Stay Bullish Upcoming Earnings AutoZone (5/26/2026)Marvell Technology (5/27/2026)PDD (5/27/2026)Synopsys (5/27/2026)Bank Of Montreal (5/27/2026)Bank of Nova Scotia (5/27/2026)Salesforce (5/27/2026)Snowflake (5/27/2026)Autodesk (5/28/2026)Costco Wholesale (5/28/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
